Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of equity and acquisition

25 Sep 2009 07:00

RNS Number : 6454Z
Omega Diagnostics Group PLC
25 September 2009
 



25 September 2009 AIM: ODX

Omega Diagnostics Group PLC

("Omega or the "Company")

Issue of Equity and Acquisition

Omega, the AIM listed medical diagnostics company, is today pleased to announce that it has raised £1million before expenses (approximately £884k net of expenses) by way of a conditional placing (the "Placing") of 5,000,000 shares of 4p each in the capital of the Company ("Placing Shares") at 20 pence per share. The Placing was oversubscribed and the Company is pleased to welcome the new institutional investors to the register. The excess demand for Placing Shares has been taken up with the Company's single largest shareholder undertaking to sell his entire stake in the Company to certain of the investors under the Placing.

The proceeds of the Placing will be used partly to fund the acquisition of Co-Tek (South West) Ltd ("Co-Tek"), a company based in Devon which produces various tests for diagnosing bacterial diseases. The business assets comprise plant and machinery, fixtures and fittingsoffice equipment, debtor balances and cash. Net assets immediately prior to the acquisition were approximately £83k. The total consideration for the business and assets is £400k in cash. Omega has raised a further £600k before expenses of working capital which strengthens the balance sheet and provides an ability to react to other opportunities within the diagnostics industry to support further growthManagement expects the transaction to be earnings enhancing in the first full year of trading.

Unaudited financial accounts for the most recently available period covering ten months to 31 July 2009 show that Co-Tek achieved revenue of £188k, gross profit of £169k, EBITDA of £125k and PBT of £119kThe Company also paid a £54k dividend in the period.   Co-Tek has a profitable track record for the past four years.

The acquisition will strengthen Omega's position in the infectious disease test market and provides scope to increase volumes through the use of its broad geographic distribution network in over 100 countries.

David Evans, Chairman of the Company commented:

"We are very pleased with the support received for the Placing from existing and new shareholders for which we give thanks. We also look forward to the positive benefits we can expect from combining Co-Tek's operations with those of the Company including significantly increased channels to market for Co-Tek's products that the acquisition provides."

The Placing is conditional on, inter alia, the Placing Shares being admitted to trading on AIM ("Admission"). Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is expected that admission will occur at 8.00 a.m. on 28 September 2009. The Placing Shares will, when issued, rank pari passu in all respects with the Company's existing ordinary shares. 

After admission of the Placing Shares the figure of 20,632,907 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules. 

For further enquiries please contact

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Nicholas Wells

Andy Roberts

Elizabeth Bowman

Walbrook PR Limited

Tel: 020 7933 8788

Ben Knowles

Paul McManus

Mob: 07900 346978

Ben.knowles@walbrookpr.com

Paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUSSNRKNRKUAR
Date   Source Headline
22nd May 202012:30 pmRNSExercise of Options and TVR
15th May 202011:05 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
13th May 20202:00 pmRNSPrice Monitoring Extension
7th May 20208:15 amRNSExercise of Options and TVR
6th May 202011:00 amRNSPrice Monitoring Extension
4th May 202011:00 amRNSExercise of Options and TVR
1st May 20202:30 pmRNSHolding(s) in Company
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202012:00 pmRNSExercise of Options and TVR
29th Apr 20205:37 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSHolding(s) in Company
28th Apr 20205:43 pmRNSHolding(s) in Company
28th Apr 20207:00 amRNSVISITECT® CD4 Advanced Disease - supply agreement
27th Apr 20204:42 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSCE-Mark of COVID-19 ELISA antibody test
24th Apr 202011:00 amRNSPrice Monitoring Extension
20th Apr 20202:05 pmRNSSecond Price Monitoring Extn
20th Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20201:24 pmRNSHolding(s) in Company
20th Apr 20201:23 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 MTA signed with Mologic Ltd
16th Apr 20205:40 pmRNSHolding(s) in Company
16th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20203:06 pmRNSHolding(s) in Company
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSCOVID-19 Consortium MOU
6th Apr 20209:30 amRNSVISITECT® CD4 Advanced Disease evaluation
6th Apr 20208:34 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSChinese Approval for Food Detective® test
2nd Apr 20207:00 amRNSTrading Update
24th Jan 20207:00 amRNSGrant of Options under Company EMI Plan
21st Jan 20203:24 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSExercise of Options and Total Voting Rights
17th Jan 202010:30 amRNSNigerian MOH approval for VISITECT CD4 350 test
8th Jan 202012:13 pmRNSHolding(s) in Company
16th Dec 20194:05 pmRNSDirector/PDMR Shareholding
9th Dec 20194:30 pmRNSHolding(s) in Company
2nd Dec 20199:00 amRNSGrant of Share Options
2nd Dec 20197:00 amRNSInterim Results
2nd Dec 20197:00 amRNSNigerian order for VISITECT® CD4
25th Nov 20197:00 amRNSUpdate on Allergy test menu
21st Nov 20197:00 amRNSInvestor results briefing
22nd Oct 201911:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.